Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 21 entries
Sorted by: Best Match Show Resources per page
Effect of gold adsorption on the conductive properties of cyclo-octasulfur microcrystals.

Journal of nanoscience and nanotechnology

Vaganova E, Leitus G, Wachtel E, Popov I, Shimoni N, Olea D, Gomez-Herrero J, Yitzchaik S.
PMID: 18283815
J Nanosci Nanotechnol. 2007 Dec;7(12):4359-64. doi: 10.1166/jnn.2007.868.

The formation of gold crystallites on the surface of S8 promotes diffusion of electrons and determines the conductive properties of the shell-core nanosystems. Conducting probe atomic microscopy and four-probe resistance measurements confirmed that Au/S8 shell-core systems exhibit electrical conductivity...

Cite
Vaganova E, Leitus G, Wachtel E, et al. Effect of gold adsorption on the conductive properties of cyclo-octasulfur microcrystals. J Nanosci Nanotechnol. 2007;7(12):4359-64doi: 10.1166/jnn.2007.868.
Vaganova, E., Leitus, G., Wachtel, E., Popov, I., Shimoni, N., Olea, D., Gomez-Herrero, J., & Yitzchaik, S. (2007). Effect of gold adsorption on the conductive properties of cyclo-octasulfur microcrystals. Journal of nanoscience and nanotechnology, 7(12), 4359-64. https://doi.org/10.1166/jnn.2007.868
Vaganova, E, et al. "Effect of gold adsorption on the conductive properties of cyclo-octasulfur microcrystals." Journal of nanoscience and nanotechnology vol. 7,12 (2007): 4359-64. doi: https://doi.org/10.1166/jnn.2007.868
Vaganova E, Leitus G, Wachtel E, Popov I, Shimoni N, Olea D, Gomez-Herrero J, Yitzchaik S. Effect of gold adsorption on the conductive properties of cyclo-octasulfur microcrystals. J Nanosci Nanotechnol. 2007 Dec;7(12):4359-64. doi: 10.1166/jnn.2007.868. PMID: 18283815.
Copy Download .nbib Format: NLM
Stability of calcium levofolinate, 5-fluorouracil and oxaliplatin (FOLFOX) mixture.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Al Sabbagh C, Agapova E, Boudy V, Mignet N.
PMID: 34053358
J Oncol Pharm Pract. 2021 May 30;10781552211020808. doi: 10.1177/10781552211020808. Epub 2021 May 30.

FOLFOX is the most common chemotherapy combination prescribed in colorectal cancer. It is composed of calcium levofolinate, 5-fluorouracil and oxaliplatin which demonstrated synergistic outcome. Nowadays, the lack of all-in-one formulation is due to the chemical composition of the pharmaceutical...

Cite
Al Sabbagh C, Agapova E, Boudy V, et al. Stability of calcium levofolinate, 5-fluorouracil and oxaliplatin (FOLFOX) mixture. J Oncol Pharm Pract. 2021;10781552211020808doi: 10.1177/10781552211020808.
Al Sabbagh, C., Agapova, E., Boudy, V., & Mignet, N. (2021). Stability of calcium levofolinate, 5-fluorouracil and oxaliplatin (FOLFOX) mixture. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 10781552211020808. https://doi.org/10.1177/10781552211020808
Al Sabbagh, Chantal, et al. "Stability of calcium levofolinate, 5-fluorouracil and oxaliplatin (FOLFOX) mixture." Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners vol. (2021): 10781552211020808. doi: https://doi.org/10.1177/10781552211020808
Al Sabbagh C, Agapova E, Boudy V, Mignet N. Stability of calcium levofolinate, 5-fluorouracil and oxaliplatin (FOLFOX) mixture. J Oncol Pharm Pract. 2021 May 30;10781552211020808. doi: 10.1177/10781552211020808. Epub 2021 May 30. PMID: 34053358.
Copy Download .nbib Format: NLM
Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs.

Biomedicines

Vagapova E, Kozlov M, Lebedev T, Ivanenko K, Leonova O, Popenko V, Spirin P, Kochetkov S, Prassolov V.
PMID: 34944663
Biomedicines. 2021 Dec 06;9(12). doi: 10.3390/biomedicines9121846.

The acquired resistance of neuroblastoma (NB) and leukemia cells to anticancer therapy remains the major challenge in the treatment of patients with these diseases. Although targeted therapy, such as receptor tyrosine kinase (RTK) inhibitors, has been introduced into clinical...

Cite
Vagapova E, Kozlov M, Lebedev T, et al. Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs. Biomedicines. 2021;9(12)doi: 10.3390/biomedicines9121846.
Vagapova, E., Kozlov, M., Lebedev, T., Ivanenko, K., Leonova, O., Popenko, V., Spirin, P., Kochetkov, S., & Prassolov, V. (2021). Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs. Biomedicines, 9(12), . https://doi.org/10.3390/biomedicines9121846
Vagapova, Elmira, et al. "Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs." Biomedicines vol. 9,12 (2021). doi: https://doi.org/10.3390/biomedicines9121846
Vagapova E, Kozlov M, Lebedev T, Ivanenko K, Leonova O, Popenko V, Spirin P, Kochetkov S, Prassolov V. Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs. Biomedicines. 2021 Dec 06;9(12). doi: 10.3390/biomedicines9121846. PMID: 34944663.
Copy Download .nbib Format: NLM
Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs.

Biomedicines

Vagapova E, Kozlov M, Lebedev T, Ivanenko K, Leonova O, Popenko V, Spirin P, Kochetkov S, Prassolov V.
PMID: 34944663
Biomedicines. 2021 Dec 06;9(12). doi: 10.3390/biomedicines9121846.

The acquired resistance of neuroblastoma (NB) and leukemia cells to anticancer therapy remains the major challenge in the treatment of patients with these diseases. Although targeted therapy, such as receptor tyrosine kinase (RTK) inhibitors, has been introduced into clinical...

Cite
Vagapova E, Kozlov M, Lebedev T, et al. Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs. Biomedicines. 2021;9(12)doi: 10.3390/biomedicines9121846.
Vagapova, E., Kozlov, M., Lebedev, T., Ivanenko, K., Leonova, O., Popenko, V., Spirin, P., Kochetkov, S., & Prassolov, V. (2021). Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs. Biomedicines, 9(12), . https://doi.org/10.3390/biomedicines9121846
Vagapova, Elmira, et al. "Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs." Biomedicines vol. 9,12 (2021). doi: https://doi.org/10.3390/biomedicines9121846
Vagapova E, Kozlov M, Lebedev T, Ivanenko K, Leonova O, Popenko V, Spirin P, Kochetkov S, Prassolov V. Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs. Biomedicines. 2021 Dec 06;9(12). doi: 10.3390/biomedicines9121846. PMID: 34944663; PMCID: PMC8698907.
Copy Download .nbib Format: NLM
Photoinduced proton transfer in a pyridine based polymer gel.

The journal of physical chemistry. B

Vaganova E, Wachtel E, Leitus G, Danovich D, Lesnichin S, Shenderovich IG, Limbach HH, Yitzchaik S.
PMID: 20666565
J Phys Chem B. 2010 Aug 26;114(33):10728-33. doi: 10.1021/jp104277r.

We describe an experimental and theoretical consideration of photoexcited proton transfer in a poly(4-vinyl pyridine)/pyridine gel. Evidence was found for two states of a multiple state process analyzed by DFT modeling. According to the latter, following irradiation at 385...

Cite
Vaganova E, Wachtel E, Leitus G, et al. Photoinduced proton transfer in a pyridine based polymer gel. J Phys Chem B. 2010;114(33):10728-33doi: 10.1021/jp104277r.
Vaganova, E., Wachtel, E., Leitus, G., Danovich, D., Lesnichin, S., Shenderovich, I. G., Limbach, H. H., & Yitzchaik, S. (2010). Photoinduced proton transfer in a pyridine based polymer gel. The journal of physical chemistry. B, 114(33), 10728-33. https://doi.org/10.1021/jp104277r
Vaganova, Evgenia, et al. "Photoinduced proton transfer in a pyridine based polymer gel." The journal of physical chemistry. B vol. 114,33 (2010): 10728-33. doi: https://doi.org/10.1021/jp104277r
Vaganova E, Wachtel E, Leitus G, Danovich D, Lesnichin S, Shenderovich IG, Limbach HH, Yitzchaik S. Photoinduced proton transfer in a pyridine based polymer gel. J Phys Chem B. 2010 Aug 26;114(33):10728-33. doi: 10.1021/jp104277r. PMID: 20666565.
Copy Download .nbib Format: NLM
Porosity inherent to chemically crosslinked polymers. Poly(N-vinylimidazole) hydrogels.

The journal of physical chemistry. B

Calvino-Casilda V, López-Peinado AJ, Vaganova E, Yitzchaik S, Pacios IE, Piérola IF.
PMID: 18281979
J Phys Chem B. 2008 Mar 13;112(10):2809-17. doi: 10.1021/jp7106473. Epub 2008 Feb 19.

Swollen polymer networks exhibit multiscale pores filled with solvent. Such porosity, inherent to cross-linked polymers, determines some of their most relevant physical properties and applications. In this research, several samples of chemically crosslinked poly(N-vinylimidazole) were synthesized with the same...

Cite
Calvino-Casilda V, López-Peinado AJ, Vaganova E, et al. Porosity inherent to chemically crosslinked polymers. Poly(N-vinylimidazole) hydrogels. J Phys Chem B. 2008;112(10):2809-17doi: 10.1021/jp7106473.
Calvino-Casilda, V., López-Peinado, A. J., Vaganova, E., Yitzchaik, S., Pacios, I. E., & Piérola, I. F. (2008). Porosity inherent to chemically crosslinked polymers. Poly(N-vinylimidazole) hydrogels. The journal of physical chemistry. B, 112(10), 2809-17. https://doi.org/10.1021/jp7106473
Calvino-Casilda, V, et al. "Porosity inherent to chemically crosslinked polymers. Poly(N-vinylimidazole) hydrogels." The journal of physical chemistry. B vol. 112,10 (2008): 2809-17. doi: https://doi.org/10.1021/jp7106473
Calvino-Casilda V, López-Peinado AJ, Vaganova E, Yitzchaik S, Pacios IE, Piérola IF. Porosity inherent to chemically crosslinked polymers. Poly(N-vinylimidazole) hydrogels. J Phys Chem B. 2008 Mar 13;112(10):2809-17. doi: 10.1021/jp7106473. Epub 2008 Feb 19. PMID: 18281979.
Copy Download .nbib Format: NLM
Blue-violet photoluminescence of 4-isopropyl-pyridine hydroxide crystals.

The journal of physical chemistry. A

Vaganova E, Wachtel E, Leitus G, Danovich D, Popov I, Dubnikova F, Yitzchaik S.
PMID: 24708153
J Phys Chem A. 2014 May 01;118(17):3061-7. doi: 10.1021/jp411879j. Epub 2014 Apr 21.

There is continuing interest in determining essential structural features of polymer gels, which display photoelectric and/or thermoelectric behavior. One such gel is the blend, poly(4-vinylpyridine-co-butyl methacrylate)/poly(4-vinylpyridine), dissolved in liquid pyridine. Following extended aeration of a three-component mixture, which serves...

Cite
Vaganova E, Wachtel E, Leitus G, et al. Blue-violet photoluminescence of 4-isopropyl-pyridine hydroxide crystals. J Phys Chem A. 2014;118(17):3061-7doi: 10.1021/jp411879j.
Vaganova, E., Wachtel, E., Leitus, G., Danovich, D., Popov, I., Dubnikova, F., & Yitzchaik, S. (2014). Blue-violet photoluminescence of 4-isopropyl-pyridine hydroxide crystals. The journal of physical chemistry. A, 118(17), 3061-7. https://doi.org/10.1021/jp411879j
Vaganova, Evgenia, et al. "Blue-violet photoluminescence of 4-isopropyl-pyridine hydroxide crystals." The journal of physical chemistry. A vol. 118,17 (2014): 3061-7. doi: https://doi.org/10.1021/jp411879j
Vaganova E, Wachtel E, Leitus G, Danovich D, Popov I, Dubnikova F, Yitzchaik S. Blue-violet photoluminescence of 4-isopropyl-pyridine hydroxide crystals. J Phys Chem A. 2014 May 01;118(17):3061-7. doi: 10.1021/jp411879j. Epub 2014 Apr 21. PMID: 24708153.
Copy Download .nbib Format: NLM
Publisher Correction: Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis.

Scientific reports

Vagapova ER, Lebedev TD, Prassolov VS.
PMID: 34462541
Sci Rep. 2021 Aug 30;11(1):17658. doi: 10.1038/s41598-021-97281-9.

No abstract available.

Cite
Vagapova ER, Lebedev TD, Prassolov VS. Publisher Correction: Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis. Sci Rep. 2021;11(1):17658doi: 10.1038/s41598-021-97281-9.
Vagapova, E. R., Lebedev, T. D., & Prassolov, V. S. (2021). Publisher Correction: Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis. Scientific reports, 11(1), 17658. https://doi.org/10.1038/s41598-021-97281-9
Vagapova, Elmira R, et al. "Publisher Correction: Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis." Scientific reports vol. 11,1 (2021): 17658. doi: https://doi.org/10.1038/s41598-021-97281-9
Vagapova ER, Lebedev TD, Prassolov VS. Publisher Correction: Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis. Sci Rep. 2021 Aug 30;11(1):17658. doi: 10.1038/s41598-021-97281-9. PMID: 34462541; PMCID: PMC8404178.
Copy Download .nbib Format: NLM
Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes.

Oncogene

Lebedev T, Vagapova E, Spirin P, Rubtsov P, Astashkova O, Mikheeva A, Sorokin M, Vladimirova U, Suntsova M, Konovalov D, Roumiantsev A, Stocking C, Buzdin A, Prassolov V.
PMID: 34556815
Oncogene. 2021 Nov;40(44):6258-6272. doi: 10.1038/s41388-021-02018-7. Epub 2021 Sep 23.

Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers, which hinders the development of targeted therapies and novel risk stratification strategies. Multikinase inhibitors have shown potential in treating high-risk NB, but their efficacy is likely...

Cite
Lebedev T, Vagapova E, Spirin P, et al. Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes. Oncogene. 2021;40(44):6258-6272doi: 10.1038/s41388-021-02018-7.
Lebedev, T., Vagapova, E., Spirin, P., Rubtsov, P., Astashkova, O., Mikheeva, A., Sorokin, M., Vladimirova, U., Suntsova, M., Konovalov, D., Roumiantsev, A., Stocking, C., Buzdin, A., & Prassolov, V. (2021). Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes. Oncogene, 40(44), 6258-6272. https://doi.org/10.1038/s41388-021-02018-7
Lebedev, Timofey, et al. "Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes." Oncogene vol. 40,44 (2021): 6258-6272. doi: https://doi.org/10.1038/s41388-021-02018-7
Lebedev T, Vagapova E, Spirin P, Rubtsov P, Astashkova O, Mikheeva A, Sorokin M, Vladimirova U, Suntsova M, Konovalov D, Roumiantsev A, Stocking C, Buzdin A, Prassolov V. Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes. Oncogene. 2021 Nov;40(44):6258-6272. doi: 10.1038/s41388-021-02018-7. Epub 2021 Sep 23. PMID: 34556815; PMCID: PMC8566230.
Copy Download .nbib Format: NLM
Stable Aqueous Colloidal Solutions of Nd.

Nanomaterials (Basel, Switzerland)

Popov A, Orlovskaya E, Shaidulin A, Vagapova E, Timofeeva E, Dolgov L, Iskhakova L, Uvarov O, Novikov G, Rähn M, Tamm A, Vanetsev A, Fedorenko S, Eliseeva S, Petoud S, Orlovskii Y.
PMID: 34835612
Nanomaterials (Basel). 2021 Oct 26;11(11). doi: 10.3390/nano11112847.

Two series of stable aqueous colloidal solutions of Nd

Cite
Popov A, Orlovskaya E, Shaidulin A, et al. Stable Aqueous Colloidal Solutions of Nd. Nanomaterials (Basel). 2021;11(11)doi: 10.3390/nano11112847.
Popov, A., Orlovskaya, E., Shaidulin, A., Vagapova, E., Timofeeva, E., Dolgov, L., Iskhakova, L., Uvarov, O., Novikov, G., Rähn, M., Tamm, A., Vanetsev, A., Fedorenko, S., Eliseeva, S., Petoud, S., & Orlovskii, Y. (2021). Stable Aqueous Colloidal Solutions of Nd. Nanomaterials (Basel, Switzerland), 11(11), . https://doi.org/10.3390/nano11112847
Popov, Alexandr, et al. "Stable Aqueous Colloidal Solutions of Nd." Nanomaterials (Basel, Switzerland) vol. 11,11 (2021). doi: https://doi.org/10.3390/nano11112847
Popov A, Orlovskaya E, Shaidulin A, Vagapova E, Timofeeva E, Dolgov L, Iskhakova L, Uvarov O, Novikov G, Rähn M, Tamm A, Vanetsev A, Fedorenko S, Eliseeva S, Petoud S, Orlovskii Y. Stable Aqueous Colloidal Solutions of Nd. Nanomaterials (Basel). 2021 Oct 26;11(11). doi: 10.3390/nano11112847. PMID: 34835612; PMCID: PMC8625732.
Copy Download .nbib Format: NLM
A Cell-Based Platform for the Investigation of Immunoproteasome Subunit β5i Expression and Biology of β5i-Containing Proteasomes.

Cells

Burov A, Funikov S, Vagapova E, Dalina A, Rezvykh A, Shyrokova E, Lebedev T, Grigorieva E, Popenko V, Leonova O, Spasskaya D, Spirin P, Prassolov V, Karpov V, Morozov A.
PMID: 34831272
Cells. 2021 Nov 05;10(11). doi: 10.3390/cells10113049.

The degradation of most intracellular proteins is a dynamic and tightly regulated process performed by proteasomes. To date, different forms of proteasomes have been identified. Currently the role of non-constitutive proteasomes (immunoproteasomes (iPs) and intermediate proteasomes (intPs)) has attracted...

Cite
Burov A, Funikov S, Vagapova E, et al. A Cell-Based Platform for the Investigation of Immunoproteasome Subunit β5i Expression and Biology of β5i-Containing Proteasomes. Cells. 2021;10(11)doi: 10.3390/cells10113049.
Burov, A., Funikov, S., Vagapova, E., Dalina, A., Rezvykh, A., Shyrokova, E., Lebedev, T., Grigorieva, E., Popenko, V., Leonova, O., Spasskaya, D., Spirin, P., Prassolov, V., Karpov, V., & Morozov, A. (2021). A Cell-Based Platform for the Investigation of Immunoproteasome Subunit β5i Expression and Biology of β5i-Containing Proteasomes. Cells, 10(11), . https://doi.org/10.3390/cells10113049
Burov, Alexander, et al. "A Cell-Based Platform for the Investigation of Immunoproteasome Subunit β5i Expression and Biology of β5i-Containing Proteasomes." Cells vol. 10,11 (2021). doi: https://doi.org/10.3390/cells10113049
Burov A, Funikov S, Vagapova E, Dalina A, Rezvykh A, Shyrokova E, Lebedev T, Grigorieva E, Popenko V, Leonova O, Spasskaya D, Spirin P, Prassolov V, Karpov V, Morozov A. A Cell-Based Platform for the Investigation of Immunoproteasome Subunit β5i Expression and Biology of β5i-Containing Proteasomes. Cells. 2021 Nov 05;10(11). doi: 10.3390/cells10113049. PMID: 34831272; PMCID: PMC8616536.
Copy Download .nbib Format: NLM
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.

The lancet. Diabetes & endocrinology

Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, Melmed S, Strasburger CJ.
PMID: 34953531
Lancet Diabetes Endocrinol. 2021 Dec 22; doi: 10.1016/S2213-8587(21)00296-5. Epub 2021 Dec 22.

BACKGROUND: Despite biochemically responding to injectable somatostatin receptor ligands (iSRLs), many patients with acromegaly experience treatment burdens. We aimed to assess maintenance of biochemical response and symptomatic control with oral octreotide capsules versus iSRLs in patients with acromegaly who...

Cite
Fleseriu M, Dreval A, Bondar I, et al. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2021;doi: 10.1016/S2213-8587(21)00296-5.
Fleseriu, M., Dreval, A., Bondar, I., Vagapova, G., Macut, D., Pokramovich, Y. G., Molitch, M. E., Leonova, N., Raverot, G., Grineva, E., Poteshkin, Y. E., Gilgun-Sherki, Y., Ludlam, W. H., Patou, G., Haviv, A., Gordon, M. B., Biermasz, N. R., Melmed, S., & Strasburger, C. J. (2021). Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. The lancet. Diabetes & endocrinology, . https://doi.org/10.1016/S2213-8587(21)00296-5
Fleseriu, Maria, et al. "Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial." The lancet. Diabetes & endocrinology vol. (2021). doi: https://doi.org/10.1016/S2213-8587(21)00296-5
Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, Melmed S, Strasburger CJ. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2021 Dec 22; doi: 10.1016/S2213-8587(21)00296-5. Epub 2021 Dec 22. PMID: 34953531.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 21 entries